Peter Nash drpnash
5 years 11 months ago
Efficacy & Safety Deucravacitinib (BMS-986165), Oral, Selective TyK2 Inhib in Patients with Active PsA Results from a Phase 2, RDBPC Trial https://t.co/s3V5NtRpuW results-from-a-phase-2-randomized-double-blind-plac/ #psa #tyk2inhib Efficacy in PsA ?top of dose response
Peter Nash drpnash
5 years 11 months ago
Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators) https://t.co/LGERY3mpe5 #febuxostat #allopurinol #CVS some cardiac reassurance feboxustat
Peter Nash drpnash
5 years 11 months ago
Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study https://t.co/F86K1Lqou7 #tofacitinib #AS Tofa works in AS , zoster no VTE seen NNH 20(per SAE) NNT 2.5(per ASAS40)
American College of Rheumatology ACRheum
5 years 11 months ago
The #ACR20 Great Debate will feature two experts discussing whether #JAK inhibitors should be used before biologics if methotrexate fails. The session runs Friday, Nov. 6., from 10:00 to 11:00 AM ET. Learn more → https://t.co/I8zTGn0Q06
The COVID Tracking Project COVID19Tracking
5 years 11 months ago
Our daily update is published. States reported record numbers of tests (1.5 million) and cases (116k). Hospitalizations continue their sharp rise. The death toll was 1,124. https://t.co/z3gxwP6EaC
ATS Clinical Problems Assembly ATSCPAssembly
5 years 11 months ago
Dr. Dinesh Khanna (@sclerodermaUM): In post-hoc analysis of focuSSed trial of tocilizumab vs. placebo, disease duration, male gender, elevated acute phase reactants, and anti-SCL-70 Ab have a larger beneficial effect on FVC in early SSc-ILD. #ATS2020 #MiniSymposia @UMIntMed 10/
Leonard Calabrese LCalabreseDO
5 years 11 months ago
One of the many HOT sessions tomorrow #ACR20 I am planning on - IFN is center stage in autoinflammatory/autoimmune/infectious diseases especially-hope they cover IFN autoantibodies!! #COVID19 - @CCalabreseDO @JYazdanyMD @canallab @MaxKonigMD @AdamJBrownMD @TiphaineLft https://t.co/uDauMkGsjX
Peter Nash drpnash
5 years 11 months ago
Association Between Changes in Pain Sensitization and Changes in Disease Activity After 12 Weeks of Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis https://t.co/DLGFcDqrus #RA #pain Pain sensitization a management issue - disease control minor benefit
Leonard Calabrese LCalabreseDO
5 years 11 months ago
Very psyched for this session tomorrow at #ACR20 on irAEs- this was a win for Twitter big time-thnxs for the shout out!!! looking for the next cut of data from the @rheum_covid alliance !!! @RheumNow @drdavidliew @CCalabreseDO @cappelliMD @HealioRheum https://t.co/qepFdLhmlV https://t.co/1jSek0sRqT
The RECIPE Study - MMF in Refractory Gout: Dr. Jack Cush
Dr. Jack Cush previews the RECIPE study, wherein MMF is used to blunt the immunogenicity of pegloticase (abstract #0952 presented at the ACR 2020 annual meeting).
Antimalarials in Pre COVID-19 Era: Dr. Janet Pope
Dr. Pope discusses abstract #0002 presented at the #ACR20 annual meeting.
RheumNow Preview by Dr. Jack Cush
Dr. Cush previews RheumNow's ACR virtual meeting coverage, and highlights new features this year: ACR IQ and ACR chat! On ACR chat, Dr. Cush wants to know: what's the burning question? Don't forget to download the virtual ACR 2020 Playbook!
Inadequate Response in Spondylitis: Dr. Olga Petryna
Dr. Petryna discusses two abstracts being presented at the ACR 2020 meeting: #0359 and #0371.
Christina Downey, MD, RhMSUS cdowneymd
5 years 11 months ago
Happening now! Session 1T001 Opening Session of #ACR20. #ACRambassador Head on over, @ACRheum! https://t.co/eErNDB8pV6
Richard Conway RichardPAConway
5 years 11 months ago
#ACR20 year in review @JYazdanyMD CIRT trial showing that MTX pneumonitis occurs but is very (very) rare. @RheumNow @jeffsparks @DanielHSolomon https://t.co/UbD4mhHBzq
